Key Takeaways Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial ...

D-cyclin proteins play a central role in cell-cycle regulation and are involved in the pathogenesis of lymphomas. In mantle-cell lymphoma, the t (11;14) translocation leads to overexpression of ...

Circle expects to advance its cyclin A/B inhibitor program into IND-enabling studies later this year and subsequently into clinical development for testing in a range of cancer types, including SCLC.

In these in vivo studies, oral administration of Circle’s Cyclin A/B inhibitor led to substantial tumor regression in both TNBC and luminal breast cancer models, with complete response observed ...

These findings indicate that Cyclin T1 is not essential for the biology of CD4 T cells, but that it is required for HIV latency reactivation. Going forward, “we are very curious to investigate in ...

Cyclin-dependent kinase inhibitors, such as the mammalian p27 Kip1 protein, regulate correct cell cycle progression and the integration of developmental signals with the core cell cycle machinery.

Its lead program, CID-078, a cyclin A/B-RxL inhibitor, is in a Phase 1 clinical trial (NCT06577987) for patients with advanced solid tumors. To learn more about Circle Pharma, please visit www ...

In a paper published in Science China Life Sciences, researchers from Sun Yat-sen Memorial Hospital found that overexpressed Cyclin D1 and CDK4 proteins, caused by accelerated translation, led to ...

Cedilla Therapeutics Inc. has synthesized cyclin-dependent kinase 2 (CDK2)/cyclin E1 inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, Cushing syndrome, Alzheimer's ...